Giorgio Treglia1,2,3,4, Arnoldo Piccardo5, Alessio Imperiale6,7, Klaus Strobel8, Philipp A Kaufmann9, John O Prior10, Luca Giovanella5. 1. Clinic of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Via Ospedale 12, 6500, Bellinzona, Switzerland. giorgio.treglia@eoc.ch. 2. Health Technology Assessment Unit, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. giorgio.treglia@eoc.ch. 3. Clinical Trial Unit, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. giorgio.treglia@eoc.ch. 4. Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland. giorgio.treglia@eoc.ch. 5. Clinic of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Via Ospedale 12, 6500, Bellinzona, Switzerland. 6. Department of Biophysics and Nuclear Medicine, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 7. Faculty of Medicine, ICube, University of Strasbourg/CNRS (UMR 7357) and FMTS, Strasbourg, France. 8. Department of Radiology and Nuclear Medicine, Lucerne Cantonal Hospital, Lucerne, Switzerland. 9. Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland. 10. Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.
Abstract
PURPOSE: Hyperparathyroidism (HPT) is a common endocrine disorder caused by hyperfunctioning parathyroid glands (HP). The correct detection and localization of HP is challenging but crucial, as it may guide surgical treatment, particularly in patients with primary HPT. There is a growing body of data regarding the role of radiolabelled choline positron emission tomography (PET) in this setting. Therefore, we performed a systematic review and meta-analysis of the diagnostic performance of this method in detecting HP in patients with HPT. METHODS: This systematic review and meta-analysis was carried out according to PRISMA guidelines. A comprehensive computer literature search of PubMed/MEDLINE, EMBASE and Cochrane Library databases for studies published through May 2018 was performed using the following search algorithm: (a) "choline" or "fluorocholine" or "F-choline" or "C-choline" or "FCH" or "CH" or "FECH" or "FMCH" and (b) "PET" or "positron emission tomography" and (c) "parathyroid" or "hyperparathyroidism". The diagnostic performance of radiolabelled choline PET was expressed as sensitivity and positive predictive value (PPV) on a per-patient and per-lesion basis and as detection rate (DR) on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI) obtained using a random-effects model. RESULTS: Eighteen studies were included in the systematic review. Fourteen articles (517 patients) were selected for the meta-analysis. The meta-analysis provided the following results on a per-patient analysis analysis: sensitivity 95% (95% CI: 92-97%), PPV 97% (95% CI: 95-98%) and DR 91% (95% CI: 87-94%). On a per-lesion analysis, pooled sensitivity and PPV were 92% (95% CI: 88-96) and 92% (95% CI: 89-95%), respectively. No significant heterogeneity was found among the selected studies. CONCLUSIONS: Radiolabelled choline PET demonstrated excellent diagnostic performance in detecting HP in patients with HPT. Large multicentre studies and cost-effectiveness analyses are needed to better define the role of this imaging method in this setting.
PURPOSE:Hyperparathyroidism (HPT) is a common endocrine disorder caused by hyperfunctioning parathyroid glands (HP). The correct detection and localization of HP is challenging but crucial, as it may guide surgical treatment, particularly in patients with primary HPT. There is a growing body of data regarding the role of radiolabelled choline positron emission tomography (PET) in this setting. Therefore, we performed a systematic review and meta-analysis of the diagnostic performance of this method in detecting HP in patients with HPT. METHODS: This systematic review and meta-analysis was carried out according to PRISMA guidelines. A comprehensive computer literature search of PubMed/MEDLINE, EMBASE and Cochrane Library databases for studies published through May 2018 was performed using the following search algorithm: (a) "choline" or "fluorocholine" or "F-choline" or "C-choline" or "FCH" or "CH" or "FECH" or "FMCH" and (b) "PET" or "positron emission tomography" and (c) "parathyroid" or "hyperparathyroidism". The diagnostic performance of radiolabelled choline PET was expressed as sensitivity and positive predictive value (PPV) on a per-patient and per-lesion basis and as detection rate (DR) on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI) obtained using a random-effects model. RESULTS: Eighteen studies were included in the systematic review. Fourteen articles (517 patients) were selected for the meta-analysis. The meta-analysis provided the following results on a per-patient analysis analysis: sensitivity 95% (95% CI: 92-97%), PPV 97% (95% CI: 95-98%) and DR 91% (95% CI: 87-94%). On a per-lesion analysis, pooled sensitivity and PPV were 92% (95% CI: 88-96) and 92% (95% CI: 89-95%), respectively. No significant heterogeneity was found among the selected studies. CONCLUSIONS: Radiolabelled choline PET demonstrated excellent diagnostic performance in detecting HP in patients with HPT. Large multicentre studies and cost-effectiveness analyses are needed to better define the role of this imaging method in this setting.
Authors: Ahmad Parvinian; Erica L Martin-Macintosh; Ajit H Goenka; Jolanta M Durski; Brian P Mullan; Brad J Kemp; Geoffrey B Johnson Journal: AJR Am J Roentgenol Date: 2017-11-15 Impact factor: 3.959
Authors: Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-22 Impact factor: 9.236
Authors: Wouter P Kluijfhout; Jesse D Pasternak; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Menno R Vriens; Bart de Keizer; Thomas A Hope; Christine M Glastonbury; Miguel H Pampaloni; Insoo Suh Journal: Radiology Date: 2017-01-25 Impact factor: 11.105
Authors: G Cocchiara; S Fazzotta; V D Palumbo; G Damiano; M Cajozzo; C Maione; S Buscemi; G Spinelli; S Ficarella; A Maffongelli; F Caternicchia; A Ignazio Lo Monte; G Buscemi Journal: Clin Ter Date: 2017 Mar-Apr
Authors: Giorgio Treglia; Elisabetta Giovannini; Davide Di Franco; Maria Lucia Calcagni; Vittoria Rufini; Maria Picchio; Alessandro Giordano Journal: Ann Nucl Med Date: 2012-05-08 Impact factor: 2.668
Authors: Arnoldo Piccardo; P Trimboli; M Rutigliani; M Puntoni; L Foppiani; L Bacigalupo; Anna Crescenzi; G Bottoni; G Treglia; F Paparo; P Del Monte; M Lanata; G Paone; G Ferrarazzo; U Catrambone; A Arlandini; L Ceriani; M Cabria; L Giovanella Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-15 Impact factor: 9.236
Authors: Bernard H E Jansen; Gem M Kramer; Matthijs C F Cysouw; Maqsood M Yaqub; Bart de Keizer; Jules Lavalaye; Jan Booij; Hebert Alberto Vargas; Michael J Morris; André N Vis; Reindert J A van Moorselaar; Otto S Hoekstra; Ronald Boellaard; Daniela E Oprea-Lager Journal: J Nucl Med Date: 2019-01-10 Impact factor: 10.057
Authors: Diego Alfonso López-Mora; Marina Sizova; Montserrat Estorch; Albert Flotats; Valle Camacho; Alejandro Fernández; Safae Abouzian; Francisco Fuentes-Ocampo; José Ignacio Pérez Garcia; Ana Isabel Chico Ballesteros; Joan Duch; Anna Domènech; Antonio Moral Duarte; Ignasi Carrió Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-09 Impact factor: 9.236
Authors: Akinyemi A Akintayo; O A Abiodun-Ojo; C Weber; J Sharma; C Cohen; G Sica; R Halkar; M M Goodman; D M Schuster Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488
Authors: Arnoldo Piccardo; Gianluca Bottoni; Luis Alejandro Boccalatte; Chiara Camponovo; Martina Musumeci; Lorenzo Bacigalupo; Carlos Collaud; Martina Ugolini; Francesco Fiz; Pierpaolo Trimboli Journal: Endocrine Date: 2021-06-25 Impact factor: 3.633
Authors: Mario Serradilla-Martín; Ana Palomares-Cano; Miguel Cantalejo-Díaz; Mónica Mogollón-González; Esther Brea-Gómez; Nuria Victoria Muñoz-Pérez; Juan Ignacio Arcelus-Martínez; Jesús María Villar-Del-Moral Journal: Gland Surg Date: 2021-03